Clinical Trials Directory

Clinical Trials Directory

Every registered clinical trial worldwide. Recruiting status, phase, sponsor, eligibility, and conditions studied. Refreshed weekly from ClinicalTrials.gov.

Trials indexed
581,105
Recruiting now
65,164
Completed
317,239
Conditions
35,940
Sponsors
49,944

Recently updated recruiting trials

StatusTrial
RecruitingA Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
AstraZeneca · Phase 3
RecruitingA Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe …
Genentech, Inc. · Phase 1 / Phase 2
RecruitingA Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE…
Eli Lilly and Company · Phase 1
RecruitingEffects of Stoma Education on Patients
Ataturk University · N/A
RecruitingThe Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammato…
Universitaire Ziekenhuizen KU Leuven · Phase 2 / Phase 3
RecruitingVenetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Un…
M.D. Anderson Cancer Center · Phase 2
RecruitingStudy of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenoco…
National Cancer Institute (NCI) · Phase 1
RecruitingTHREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins
National Institute of Allergy and Infectious Diseases (NIAID) · N/A
RecruitingC-SMART vs BE Well for Patients With Brain Tumors
Virginia Commonwealth University · N/A
RecruitingBeamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2…
Boehringer Ingelheim · Phase 2
RecruitingFactors Associated With Breast Cancer Risks and Outcomes
Memorial Sloan Kettering Cancer Center · —
RecruitingAn Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-o…
Hoffmann-La Roche · —
RecruitingAn Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Ga…
Jiangsu HengRui Medicine Co., Ltd. · Phase 3
RecruitingClevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Zeenat Qureshi Stroke Institute · —
RecruitingPredictors of Poor Prognosis in HFpEF
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · —

All recruiting trials →

Most-studied conditions

  1. Healthy — 10,938
  2. Breast Cancer — 8,626
  3. Obesity — 7,397
  4. Stroke — 5,152
  5. Hypertension — 4,556
  6. Depression — 4,480
  7. Pain — 4,455
  8. Prostate Cancer — 4,361
  9. Cancer — 3,882
  10. HIV Infections — 3,863
  11. Coronary Artery Disease — 3,680
  12. Heart Failure — 3,667
  13. Asthma — 3,628
  14. Diabetes Mellitus, Type 2 — 3,597
  15. Colorectal Cancer — 3,409
  16. COVID-19 — 3,330
  17. Anxiety — 3,185
  18. Non-small Cell Lung Cancer — 3,152
  19. Lung Cancer — 3,057
  20. Cardiovascular Diseases — 3,000

All conditions →

Most-prolific sponsors

Assiut University — 4,619
Cairo University — 4,499
GlaxoSmithKline — 3,588
National Cancer Institute (NCI) — 3,536
Assistance Publique - Hôpitaux de Paris — 3,460
AstraZeneca — 3,413
Pfizer — 3,253
Mayo Clinic — 3,183
M.D. Anderson Cancer Center — 2,982
Novartis Pharmaceuticals — 2,630
National Taiwan University Hospital — 2,524
Massachusetts General Hospital — 2,513
National Institute of Allergy and Infectious Diseases (NIAID) — 2,429
Boehringer Ingelheim — 2,271
Merck Sharp & Dohme LLC — 2,113
University of California, San Francisco — 2,103
Stanford University — 2,098
Hoffmann-La Roche — 2,068

All sponsors →